Status:
UNKNOWN
Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study
Lead Sponsor:
Geha Mental Health Center
Conditions:
Depression
Eligibility:
All Genders
6-18 years
Phase:
PHASE4
Brief Summary
The aim of the present study is to prospectively assess the anti-depressant effectiveness of reboxetine in children and adolescents, as compared with fluoxetine, in a randomized controlled open-label ...
Detailed Description
Introduction: Depression is a prevalent disorder involving 3% of children and 8% of adolescents (Birmaher et al, 1996). Reboxetine, a highly selective norepinephrine reuptake inhibitor, is a represent...
Eligibility Criteria
Inclusion
- A diagnosis of major depressive disorder or a dysthimic disorder according to DSM-IV-TR.
- Drug naïve or without chronic medication for at least one month.
- Only children who agree to participate and whose parents will sign and informed consent form will be included.
Exclusion
- A diagnosis of a psychotic disorder or bipolar disorder.
- Mental retardation.
- Alcohol or drug abuse
- Chronic medical condition
- Girls (\> 12 years) will not be included in the study if a possibility of pregnancy during the study exists.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00426946
Start Date
January 1 2005
Last Update
January 25 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tel Aviv Community Mental Helath Center
Tel Aviv, Israel